Back to top

Image: Bigstock

bluebird bio, Inc.

Read MoreHide Full Article

bluebird does not have any approved products in its portfolio and an unfavorable outcome from any of the ongoing studies will be huge setback. Additionally, the markets bluebird is targeting is getting increasingly competitive. The company is highly dependent on Celgene for the development of its candidates. Termination of the agreement with Celgene will have a negative impact on the company's growth prospects. Moreover, R&D spend is expected to increase significantly as it advances its pipeline candidates to late-stage studies. Shares of the company have underperformed the industry in the year so far. Nevertheless, the company has an impressive pipeline of gene therapies for genetic diseases and cancer.  The company is currently conducting five clinical studies for its LentiGlobin product candidate and reported positive data from two of its studies. The company is also developing CAR T therapies in collaboration with Celgene for myeloma.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

bluebird bio, Inc. (BLUE) - free report >>